PURE-EXO
DEAD

Serial Number

90357314

Owner

ILIAS Biologics Inc.

Attorney

Janice Housey

Filing Date

Dec 3, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PURE-EXO Trademark

Serial Number: 90357314

PURE-EXO is a trademark filed by ILIAS Biologics Inc. on December 3, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ILIAS Biologics Inc. (11 trademarks)

40-20 Techno 6-ro, Yuseong-gu
Daejeon 34014 , KR

Entity Type: 03

Trademark Details

Filing Date

December 3, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemicial drug for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use

Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose

Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 5, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 5, 2025 ABN2
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 23, 2024 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 21, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 21, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Oct 21, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 21, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 21, 2024 REAP
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 18, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 18, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 18, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2024 CRFA
ASSIGNED TO LIE
Jun 24, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 26, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 26, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 26, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 26, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 1, 2024 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jul 6, 2023 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 18, 2023 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 12, 2022 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 18, 2022 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 5, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 5, 2022 GNSL
SUSPENSION LETTER WRITTEN
Jan 5, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 3, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 3, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 3, 2021 CNRT
ASSIGNED TO EXAMINER
May 20, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 9, 2021 NWOS
NEW APPLICATION ENTERED
Dec 7, 2020 NWAP